人民财讯8月14日电，企查查APP显示，近日，上海海望合纵私募基金合伙企业(有限合伙)发生工商变 更，新增康希通信、安集科技、翱捷科技为股东。企查查信息显示，该企业成立于2025年3月，注册资 本21.1亿元，经营范围包含：以私募基金从事股权投资、投资管理、资产管理等活动。 ...

Meeting Overview - The first extraordinary general meeting of Jiangsu Kangzhong Digital Medical Technology Co., Ltd. was held on August 1, 2025, at the company's conference room in Suzhou Industrial Park [2][4] - All 9 current directors and 3 supervisors attended the meeting, along with the board secretary and other senior executives [4] Voting and Resolutions - The meeting adopted a combination of on-site and online voting methods, and was presided over by Chairman Jianqiang Liu [4] - All proposed resolutions were passed, including the cancellation of the supervisory board and amendments to the company's articles of association, shareholder meeting rules, board meeting rules, independent director work system, and cumulative voting implementation details [5][6] Legal Compliance - The meeting's procedures, attendance, and voting methods were confirmed to comply with the Company Law, Securities Law, and the company's own regulations by the witnessing lawyers from Zhonglun Law Firm [6]

证券代码：688607 证券简称：康众医疗 公告编号：2025-031 江苏康众数字医疗科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 1、本次股东大会采用现场投票和网络投票相结合的方式进行表决； 2、本次会议由公司董事会召集，董事长 JIANQIANG LIU（刘建强）先生主持； 3、本次会议的召集召开程序、表决方式和表决程序符合《公司法》及《公司章 程》的规定，会议合法有效。 （五） 公司董事和董事会秘书的出席情况 3、 董事会秘书尹晟先生出席了本次会议；其他高管的列席本次会议。 二、 议案审议情况 （一） 股东会召开的时间：2025 年 8 月 1 日 （二） 股东会召开的地点：苏州工业园区星湖街 218 号生物纳米园 B3 楼 501 室公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 42 | ...

2025 年第一次临时股东会的 法律意见书 北京市中伦律师事务所 关于江苏康众数字医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江苏康众数字医疗科技股 份有限公司（以下简称"公司"）的委托，就公司 2025 年第一次临时股东会（以 下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）和上海证券交易所发 布的《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等现 行有效的法律、法规、规范性文件及《江苏康众数字医疗科技股份有限公司章程》 （以下简称"《公司章程》"）、《江苏康众数字医疗科技股份有限公司股东会 议事规则》（以下简称"《股东会议事规则》"）的有关规定，出具本法律意见 书。 致：江苏康众数字医疗科技股份有限公司 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 ...

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on August 1, 2025, with specific procedures outlined for attendance and voting [1][4][5] - Shareholders must present identification and relevant documents to confirm their attendance and voting rights [2][3] - The meeting will include a series of agenda items, including the election of voting and monitoring members, and the discussion and voting on various proposals [8] Group 2 - Proposal one involves the cancellation of the supervisory board and the revision of the company's articles of association, transferring the supervisory functions to the audit committee of the board [6][7] - Proposal two focuses on revising the rules governing shareholder meetings to enhance operational efficiency and protect shareholder rights [9] - Proposal three aims to revise the rules governing board meetings to promote sustainable development and operational efficiency [10] - Proposal four seeks to enhance the efficiency and independence of independent directors through revisions to the independent director working system [12] - Proposal five is about revising the implementation details of the cumulative voting system to improve decision-making efficiency at shareholder meetings [12]

江苏康众数字医疗科技股份有限公司 2025 年第一次临时股东会会议资料 江苏康众数字医疗科技股份有限公司 2025 年第一次临时股东会会议资料 证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司 2025 年第一次临时股东会会议资料 二〇二五年八月 1 / 13 2025 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股 东会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》以 及《江苏康众数字医疗科技股份有限公司章程》《江苏康众数字医疗科技股份有 限公司股东会议事规则》的相关规定，特制定 2025 年第一次临时股东会会议须 知： 一、为确认出席本次会议的股东或其代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 江苏康众数字医疗科技股份有限公司 2025 年第一次临时股东会会议资料 目录 | 2025 | 年第一次临时股东会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第一次临时股东会会议议程 | 6 | | 2025 | 年第一次临 ...

Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

Core Viewpoint - The AI Fund Zhaoshang China Opportunity Stock (001749) reported a profit of 4.3172 million yuan for Q2 2025, with a weighted average profit per fund share of 0.0328 yuan, indicating a net value growth rate of 2.48% during the period [3]. Fund Performance - As of the end of Q2 2025, the fund's scale was 183 million yuan [15]. - The fund's unit net value was 1.452 yuan as of July 17 [3]. - The fund manager, Li Huajian, oversees two funds, both of which have shown positive returns over the past year [3]. - The fund's one-year compounded net value growth rate reached 18.53%, ranking it 87 out of 166 comparable funds [3]. - Over the past three months, the fund's compounded net value growth rate was 9.75%, ranking 86 out of 167 comparable funds [3]. - The fund's six-month compounded net value growth rate was 5.60%, ranking 122 out of 167 comparable funds [3]. - The fund's three-year compounded net value growth rate was -29.86%, ranking 141 out of 159 comparable funds [3]. Risk Metrics - The fund's three-year Sharpe ratio was -0.2043, ranking 130 out of 159 comparable funds [8]. - The maximum drawdown over the past three years was 50.43%, ranking 14 out of 158 comparable funds [10]. - The largest single-quarter drawdown occurred in Q1 2021, at 23.46% [10]. Investment Strategy - The fund management remains optimistic about the structural market trends in A-shares, citing improvements in domestic economic growth and structural transformation [3]. - The fund is particularly focused on investment opportunities in sectors such as AI, pharmaceuticals, military industry, and media [3]. Portfolio Composition - As of the end of Q2 2025, the fund's top ten holdings included Changying Tong, Zhongke Feice, Jingyi Equipment, Boqian New Materials, Youfang Technology, Hudian Co., Changchuan Technology, Xinyi Sheng, Jinqiao Information, and Chip Origin Technology [18]. - The average stock position over the past three years was 89.19%, compared to the industry average of 87.97% [13]. - The fund reached a maximum stock position of 93.14% at the end of H1 2025, with a minimum of 79.84% at the end of H1 2024 [13].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on August 1, 2025, at 14:30 [1] - The meeting will take place at the company's conference room located at 501, B3 Building, Bio-Nano Park, 218 Xinghu Street, Suzhou Industrial Park [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system on the day of the meeting from 9:15 to 15:00 [1][2] - Specific voting times for the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders must complete identity verification to vote on the internet platform [2] Agenda Items - The meeting will review a proposal to cancel the supervisory board and amend the company's articles of association [2] - The proposal has already been approved by the company's board and supervisory board in previous meetings [2] Attendance Requirements - Shareholders registered by the close of trading on July 25, 2025, are eligible to attend the meeting [4] - Shareholders can appoint a proxy to attend and vote on their behalf [4] - Specific documentation is required for both corporate and individual shareholders to register for the meeting [5] Additional Information - Shareholders wishing to attend must confirm their attendance by July 31, 2025, via email [5] - Contact details for inquiries include a phone number and email address for the company [6]

Group 1 - The company has decided to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors [1][2] - The proposal to cancel the supervisory board and amend the articles of association will be submitted for approval at the company's first extraordinary general meeting of shareholders in 2025 [1][2] - The internal control systems related to the supervisory board will be abolished, and corresponding amendments will be made to the articles of association and the rules of procedure for the general meeting of shareholders [1][2] Group 2 - The amendments to the articles of association aim to improve the corporate governance structure and enhance compliance with relevant laws and regulations [2] - Specific amendments include changes to the legal representative's role, the company's registered capital, and the rights and obligations of shareholders [2][4] - The new articles of association will ensure that the company operates in accordance with the latest legal requirements and best practices [2][4]